-
11:21:35 PM

ACAD Stock News

09/19/23 4:05 PM
Nasdaq : ACAD
management
Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
Acadia Pharmaceuticals Inc. today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications. Kildani will be responsible for leading investor relations and corporate communications and serve as a member of the company’ s Executive Management Committee. Kildani earned a bachelor’ s degree in...
RHEA-AI
neutral
08/02/23 4:05 PM
Nasdaq : ACAD
earnings
Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview
Acadia Pharmaceuticals Inc. today announced its financial results for the second quarter ended June 30, 2023.. “Our second quarter 2023 results reflect strong performances from both commercial franchises. Total net product sales, comprised of NUPLAZID and DAYBUE were $165.2 million for the three months ended June 30, 2023, and were $283.7 million for the...
RHEA-AI
neutral
07/24/23 4:05 PM
Nasdaq : ACAD
management
Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer
Acadia Pharmaceuticals Inc. announced today the appointment of Dr. Oliver served as SVP, Head of Global Business Development& Licensing and Alliance Management, as well as Chief Operations Officer, U.S. and Europe at Simcere Pharmaceutical Group. Oliver.“ The recent success of DAYBUE, originally partnered for North America in 2018, together with the recent...
RHEA-AI
neutral
07/19/23 4:04 PM
Nasdaq : ACAD
earnings
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023
Acadia Pharmaceuticals Inc. today announced that it will report second quarter financial results on Wednesday, August 2, 2023, after the close of the U.S. financial markets. Acadia’ s management team will also host a conference call and webcast on August 2, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call will...
RHEA-AI
neutral
07/13/23 4:05 PM
Nasdaq : ACAD
acquisition
Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome
In addition to expanding access to trofinetide outside of North America, this agreement gives Acadia exclusive worldwide rights to NNZ-2591 in both Rett syndrome and Fragile X syndrome. This deal also enables Acadia to leverage insights from our successful U.S. launch of DAYBUE in other global territories. Acadia intends to submit a New Drug Submission for...
RHEA-AI
neutral